Applied BioCode Reports Record Financial Results for the First Half of 2026; Revenue Increases 81% Year Over Year, Driven by Strong U.S. Molecular Diagnostics Growth

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #Earnings--Applied BioCode, Inc., a leader in high-throughput multiplex molecular diagnostics, today announced financial results for the six months ended June 30, 2026. For the six months ended June 30, 2026, the Company reported consolidated revenue of $13.59 million, an 81% increase from the same period in 2025. This performance was driven by expansion of the Company's installed base in U.S. clinical and veterinary laboratories and increased utilizat